‘Human–machine hybrid AI diagnostic system’ rolls into Rochester

The Mayo Clinic’s flagship campus in Minnesota is installing an AI-powered patient triage and prediction platform.

Developed and marketed by Israeli startup Diagnostic Robotics, the system is designed to facilitate more efficient and clinically appropriate decisionmaking in emergency settings.

Along with improving care quality and optimizing lengths of stay, the software additionally aims to help healthcare workers avoid burnout by smoothing peaks and valleys in their workloads.

According to coverage by the Israel-based outlet NoCamels.com, the platform is a “human–machine hybrid AI diagnostic system” that helps the humans in the equation—emergency clinicians—make the right calls on triaging and admitting patients.

The technology does so by delivering a hospitalization risk score. Its AI algorithms were trained on multiple millions of data points, including 27 million patient visits, NoCamels reports.

The outlet notes that, earlier this year, Diagnostic Robotics adapted the system for COVID-19 care and worked with the state government of Rhode Island to implement it there.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.